Evidence map›Paper›PMID 32855438›Full record

ArticleLeukemia2020

Revised 15-item MDS-specific frailty scale maintains prognostic potential.

Bo A Wan, Aziz Nazha, Rebecca Starkman, Shabbir Alibhai, Richard A Wells, Michelle Geddes, Nancy Zhu, Mary-Margaret Keating, Brian Leber, Lisa Chodirker and 18 more

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. [Prognostic value of the FS-15 frailty score in patients with myelodysplastic syndromes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Advances in Management for Older Adults With Hematologic Malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Bo A WanHematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Aziz NazhaHematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Rebecca StarkmanHematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Shabbir AlibhaiGeriatric Medicine/Oncology, University Health Network, Toronto, ON, Canada.
Richard A WellsHematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Michelle GeddesHematology/Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada.
Nancy ZhuHematology, University of Alberta Hospital, Edmonton, AB, Canada.
Mary-Margaret KeatingHematology/Oncology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
Brian LeberDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Lisa ChodirkerHematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Mitchell SabloffHematology/Oncology, University of Ottawa, Ottawa, ON, Canada.ORCID http://orcid.org/0000-0002-0122-6138
Grace ChristouHematology/Oncology, University of Ottawa, Ottawa, ON, Canada.
Heather A LeitchHematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Eve St-HilaireHematology/Oncology, Dr. Georges-L-Dumont University Centre, Moncton, NB, Canada.
Nicholas FinnHematology/Oncology, Dr. Georges-L-Dumont University Centre, Moncton, NB, Canada.
April ShamyHematology/Oncology, Jewish General Hospital, Montreal, QC, Canada.
Karen W L YeeHematology/Oncology, Princess Margaret Hospital, Toronto, ON, Canada.
John StorringHematology, McGill University Health Centre-Royal Victoria Hospital, Montreal, QC, Canada.
Thomas J NevillHematology/Oncology, Vancouver General Hospital, Vancouver, BC, Canada.
Robert DelageHematology/Oncology, Centre de Recherche du CHU de Quebec-Universite Laval, Quebec City, QC, Canada.
Mohamed ElemaryHematology, Saskatoon Cancer Centre, Saskatoon, SK, Canada.
Versha BanerjiResearch Institute in Oncology and Hematology, CancerCare Manitoba & Departments of Internal Medicine and Biochemistry & Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Anne ParmentierHematology Clinical Trials, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Mohammad SiddiquiHematology Clinical Trials, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Aksharh KirubananthaanHematology Clinical Trials, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Alexandre MamedovHematology Clinical Trials, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Liying ZhangHematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Rena BucksteinHematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. rena.buckstein@sunnybrook.ca.ORCID http://orcid.org/0000-0001-9520-7386

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FrailtyMyelodysplastic SyndromesHumansPrognosisRisk Factors

Identifiers

PMID32855438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.